Compagnie Lombard Odier SCmA Boosts Holdings in Johnson & Johnson (NYSE:JNJ)

Compagnie Lombard Odier SCmA lifted its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 2.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 72,935 shares of the company’s stock after buying an additional 2,032 shares during the period. Compagnie Lombard Odier SCmA’s holdings in Johnson & Johnson were worth $12,948,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Zullo Investment Group Inc. boosted its stake in Johnson & Johnson by 1.8% during the 2nd quarter. Zullo Investment Group Inc. now owns 16,491 shares of the company’s stock worth $2,927,000 after purchasing an additional 285 shares during the period. Okabena Investment Services Inc. boosted its stake in Johnson & Johnson by 3.8% during the 2nd quarter. Okabena Investment Services Inc. now owns 4,968 shares of the company’s stock worth $882,000 after purchasing an additional 184 shares during the period. Rezny Wealth Management Inc. acquired a new stake in Johnson & Johnson during the 2nd quarter worth $1,133,000. Capital Asset Advisory Services LLC boosted its stake in Johnson & Johnson by 7.2% during the 2nd quarter. Capital Asset Advisory Services LLC now owns 17,510 shares of the company’s stock worth $3,108,000 after purchasing an additional 1,172 shares during the period. Finally, Woodard & Co. Asset Management Group Inc. ADV boosted its stake in Johnson & Johnson by 7.6% during the 2nd quarter. Woodard & Co. Asset Management Group Inc. ADV now owns 15,886 shares of the company’s stock worth $2,820,000 after purchasing an additional 1,122 shares during the period. 68.59% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 16,410 shares of Johnson & Johnson stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the completion of the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,366,753.62. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, EVP Kathryn E. Wengel sold 16,410 shares of the business’s stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total value of $2,845,822.20. Following the completion of the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,366,753.62. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Robert J. Decker sold 16,928 shares of the business’s stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,707,775. The disclosure for this sale can be found here. Insiders sold a total of 135,723 shares of company stock worth $23,192,574 over the last ninety days. 0.35% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Citigroup reduced their target price on shares of Johnson & Johnson from $201.00 to $198.00 in a research note on Wednesday, October 5th. Bank of America reduced their target price on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research note on Friday, October 14th. Sanford C. Bernstein reduced their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Barclays assumed coverage on shares of Johnson & Johnson in a research note on Monday, October 17th. They issued an “equal weight” rating and a $175.00 target price for the company. Finally, Morgan Stanley reduced their target price on shares of Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 19th. Seven investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $181.33.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $176.82 on Wednesday. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. The firm has a 50-day moving average price of $168.35 and a two-hundred day moving average price of $171.28. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The company has a market capitalization of $462.29 billion, a P/E ratio of 24.63, a price-to-earnings-growth ratio of 3.49 and a beta of 0.57.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.49 by $0.06. The firm had revenue of $23.79 billion during the quarter, compared to the consensus estimate of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period last year, the firm posted $2.60 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson announced that its board has initiated a share repurchase plan on Wednesday, September 14th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 1.2% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board believes its shares are undervalued.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be issued a dividend of $1.13 per share. The ex-dividend date is Monday, November 21st. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.56%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.